Abcam ups rabbit mAb presence with acquisition of Calico Biolabs

monoclonal antibodies
U.K. life sciences company Abcam expanded its presence in rabbit monoclonal antibodies with the acquisition of California’s Calico Biolabs. (Novasep)

U.K. life sciences company Abcam has expanded its presence in rabbit monoclonal antibodies with the acquisition of California’s Calico Biolabs for an undisclosed price.

Calico develops custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies. With the deal, Abcam gets Calico’s catalog of ready-made CAL antibodies for immunohistochemistry as well as its custom development services.

“This acquisition significantly expands our leadership in recombinant rabbit monoclonal antibody technology,” Joyce Young, an Abcam vice president, said in a statement. “The combination of our complementary antibody engineering capabilities will further support our mission to provide our customers with access to the best antibodies for both today’s and tomorrow’s targets of interest.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Last year, Abcam made a run at gene editing specialist Horizon Discovery for a deal that would have been worth $367 million. However, Horizon rejected the offer and instead of sweetening the deal Abcam hit the pause button on the move.

Suggested Articles

Qiagen is collaborating with Ares Genetics to develop new bioinformatics and assay solutions for research targeting antibiotic-resistant bacteria.

STA Pharmaceutical has signed an exclusive technology and marketing deal with Swiss biotech BioLingus.

Clinerion is partnering with Citeline to give clinical researchers a more comprehensive approach to making evidence-based decisions.